

DIGNITANA

Clinically superior scalp cooling

FEBRUARY 15 • 2024



**Positive EBITDA, continued
growth and high margin**

Q4 23

QUARTERLY REPORT

Positive EBITDA, continued growth and high margin

Financial highlights Q4 2023

- Net sales amounted to 21.3 MSEK (20.2), an increase of 5 percent over the same period in 2022
- Operating Result amounted to -3.7 MSEK (-10.9)
- Net Result after financial items amounted to -5.1 MSEK (-12.0).
- EBITDA for the Fourth Quarter is positive at 138 TSEK (-7250).
- Earnings per share were -0.07 SEK (-0.17)
- Cash Balance amounted to 6.0 MSEK (8.9)
- Average Daily Treatment Revenue (ADTR)* was 238 TSEK (229) in the quarter, an increase of 4 percent over the same period in 2022.

Financial highlights Full Year 2023

- Net sales amounted to 86.1 MSEK (73.0), an increase of 18 percent over 2022.
- Operating Result amounted to -15.0 MSEK (-20.6).
- Net Result after financial items amounted to -17.4 MSEK (-22.4).
- EBITDA for the year is positive at 0.1 MSEK (-6.8).
- Earnings per share were -0.25 SEK (-0.34).

” With a strong focus on establishing stable operating expenses to support our scale up strategy, we have grown with high margin while reducing loss.

– Catarina Löwenadler, CEO

Key Figures

DIGNITANA GROUP	Q4 2023	Q4 2022	FY 2023	FY 2022
Net sales, TSEK	21,266	20,245	86,063	72,995
Total revenues, TSEK	21,916	21,421	89,025	83,849
Net profit after financial items, TSEK	-4,943	-11,996	-17,228	-22,396
Cash and bank balances, TSEK	6,027	8,869	6,027	8,869
Earnings per share before and after dilution, SEK	-0.07	-0.17	-0.25	-0.34
Average Daily Treatment revenue, TSEK	238	229	239	203

* ADTR includes pay-per-treatment revenue from patients and facilities in the U.S. Does not include lease revenue or disposable sales.

DIGNITANA'S VISION IS TO ENSURE THAT CANCER PATIENTS CAN MAINTAIN DIGNITY AND QUALITY OF LIFE DURING AND AFTER CANCER TREATMENT.

Business highlights during the period

- Dignitana announced a sales and marketing partnership with InfuSystem to provide scalp in the United States.
- Seven states in the southeastern United States fall under the Local Coverage Determination issued by Palmetto GBA providing coverage for scalp cooling to Medicare recipients as of November 2023.
- Dignitana announced the US Centers for Medicare & Medicaid Services will continue to support scalp cooling however at a reduced average rate beginning January 2024.
- Dignitana AB appointed the Nomination Committee for the 2024 Annual General Meeting.

Business highlights after the period

- Dignitana convenes Training Academy bringing distributors to Lund Headquarters
- Preliminary result of DigniCap Delta study in Uruguay demonstrate very high efficacy compared to previous studies.
- Dignitana signs OncoMedical for distribution in Switzerland and Liechtenstein
- DigniCap Delta received market approval in Japan with Konica Minolta as Dignitana's Distribution partner

Business highlights Full Year 2023

- Science International Corporation was announced as Dignitana's distributor in Hong Kong and Macao.
- Dignitana co-sponsored a scalp cooling session at the Multinational Association of Supportive Care in Cancer conference in Japan along with exhibiting at the conference.
- A Medicare Local Coverage Determination for Medicare for scalp cooling therapy took effect in seven states in the southeastern US.
- Five year follow up results from the DigniCap pivotal trial were published in the Supportive Care in Cancer journal demonstrating both safety and efficacy in the first long term study of scalp cooling
- Dignitanas's partnership with oneservice expanded to provide service in the field to DigniCap customers in Europe.
- DigniCap Delta was introduced to customers in Mexico by Celeritas, DigniCap's longtime partner.

Positive EBITDA, continued growth and high margin

It has been an important year of development for Dignitana's growth. With a strong focus on establishing stable operating expenses to support our scale up strategy, we have grown with high margin while reducing loss. Making investments in infrastructure and digitalization now paves the way for more profitable growth moving forward.

Dignitana currently has 90 percent recurring revenues and a circular business model to efficiently use assets and redeploy devices where they are most beneficial. The period closed out with continued growth shown by an increase of five percent in net sales with a high margin of 69 percent.

The 18 percent growth in net sales that we have achieved this year comes while stabilizing operating expenses. The improvement in cost controls is illustrated when we compare Q4 year over year and full year numbers:

- Operating profit shows a reduction of loss by 66 percent Q4 2023 over Q4 2022 and a reduction of loss of 27 percent full year 2023 to 2022.
- Net result shows a 58 percent reduction of loss Q4 2023 over Q4 2022 and a 23 percent reduction of loss for the full year 2023 vs. 2022.
- Q4 2023 posts a 21 percent decrease in Operating Expenses, with a net change of zero in Operating Expenses for full year 2023 vs 2022.

Overall, this points to a more efficient infrastructure, and we are happy to see this pay off with EBITDA positive again in the fourth period and our first ever full year of positive EBITDA.

This has been achieved at the same time that we have made investments to generate profitable growth as we move forward. Specifically, digital portal for e-commerce and training; test equipment to enable service in the field; distributor academy; key process improvements in operations, quality, and finance; clinical studies; and supported a wide range of reimbursement initiatives. We now feel we have the infrastructure, competence, and partnership in place to accelerate growth in a scalable way.

A key differentiator for DigniCap is our exemplary recommendation rate of 94 percent. This level of patient satisfaction, coupled with ongoing support of our clinical customers, provides solid evidence of happy patients and consistently high clinical outcomes.

Further supporting this success and the clinical superiority of our product, shortly after the period our partner in Uruguay released preliminary study data demonstrating the superiority of DigniCap Delta with a success rate of 79 percent – 13 percent higher than the C3 device used in the DigniCap pivotal trial.

with 90 percent of patients completing the study losing less than 50 percent of their hair and the remaining 10 percent at the 50 percent mark designating success.

In our primary US market we kicked off a sales and marketing partnership with InfuSystem, providing access to infusion centers nationwide and customer response to this new contact point has been very positive.

Together with increased customer facing activities in Q4 and beginning of 2024, we have an accelerated growth in number of orders with 8 new contracts signed in January in United States.

On the global front this quarter we added DigniCap Delta devices in Chile, Australia, Italy and Hong Kong. Several important activities were also announced shortly after the period:

- OncoMedical joined us as a new distributor for Switzerland and Liechtenstein. Switzerland has a high rate of private clinics and several C3 customers are ready to convert to the latest technology available only in DigniCap Delta.
- In January DigniCap Delta received market approval in Japan and Konica Minolta will proceed as a market authorization holder to expand into the Japanese market. This agreement kicked off with an initial order in February and a second order for several devices will be placed in early spring 2024 to prepare for launch.
- Pulling together the key players in these global activities, in late January we convened the first ever Distributor Academy in Lund, training 16 people from 5 distributors from Japan, Hong Kong, Mexico, Chile and Switzerland in clinical skills and technical support. This academy fosters accelerated growth and provides more efficient customer support and service, while also building valuable relationships between our partners for future collaboration and shared resources.

In closing, we see many businesses around the world struggling now facing issues related to inflation, rising costs and personnel shortages. I am very pleased that our team continues to work hard to generate growth while focusing on our overall strategy, despite the many challenges in our current business climate. We thank our shareholders for their ongoing support as we continue our goal of delivering value to our investors while improving quality of life for patients.



Catarina Löwenadler, CEO
Dignitana AB

The Company

Dignitana AB is a medical technology company based in Lund, Sweden and publicly traded on Nasdaq First North Growth Market in Sweden. Company headquarters are in Lund, Sweden and U.S. operations are based in Dallas, Texas. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Redeye AB is Certified Adviser.

The Company produces The DigniCap Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy to improve well-being and quality of life. The DigniCap Scalp Cooling System was invented in 1999 by a Swedish oncology nurse.

DigniCap has been on the market in Europe since 2001 and has had FDA clearance since 2015 to provide continuous scalp cooling with high efficacy, safety, and acceptable patient comfort. In 2017 Dignitana received expanded clearance from the FDA allowing DigniCap to be used by patients receiving chemotherapy to treat other solid


tumors in addition to the original indication for use by patients with breast cancer. In 2019 Dignitana introduced the next generation DigniCap Delta and the technologically advanced DigniCap Delta model received CE Marking and FDA clearance that year.

Scalp cooling is recognized as standard of care by numerous organizations around the world. European Society for Medical Oncology (ESMO) added scalp cooling as a Category IIB treatment recommendation in 2020 and Cancer Australia added scalp cooling to its Fall 2020 update providing guidance for the management of early breast cancer patients. In the United States clinical recommendations introduced in 2019 and 2020 by the National Comprehensive Cancer Network® and a policy reaffirmation by the American Medical Association in 2022 all contribute to a solid foundation for scalp cooling to become standard of care in the United States.

Business model

The availability of scalp cooling continues to expand as we work toward scalp cooling becoming standard of care providing access to more patients. Dignitana has two business models that each include an ongoing revenue stream from the sale of consumables. In the United States devices are leased to providers and the Company utilizes a pay-per-treatment model. Dignitana offers a buy and bill model that supports reimbursement initiatives. As reimbursement and coverage become more standard, we are transitioning providers to this model that is widely used in healthcare.

Outside the U.S. devices are sold to medical facilities and the company also receives revenue from service and maintenance agreements. For global markets that do not have a pay-per-treatment model, the focus is on creating a more sustainable recurring revenue stream from unit sales, lease agreements, service and maintenance fees, and sales of product disposables and supplies.



Reimbursement

Dignitana is committed to ensuring scalp cooling is available to every cancer patient and reimbursement is a critical factor in patient access and affordability. Health care providers are key partners in our efforts to increase accessibility to improve quality of life for as many cancer patients as possible. Dignitana recognizes that providers allocate a range of resources to scalp cooling therapy and their clinical expertise, direct patient care, and skilled operation of the DigniCap device by trained personnel ensure that DigniCap patients have the most successful clinical outcomes possible. The buy and bill model Dignitana offers facilitates a pathway for providers to be reimbursed for the specialized service they are providing to patients.

Since 2021 Dignitana has led the way in reimbursement efforts for scalp cooling in the U.S., including work supporting the introduction of CPT® codes for scalp cooling, a 2022 rate assignment from the Centers for Medicare & Medicaid Services (CMS), and a Local Coverage Determination (LCD) from the Palmetto Medicare Administrative Contractor (MAC) which administers

Medicare benefits in seven states in the southeastern United States. This provides a pathway for successful reimbursement of Medicare claims for patients in the seven-state service area. This is the first such LCD and further advances support for health care providers to receive reimbursement to administer FDA-cleared scalp cooling therapy.

Dignitana continues to work with commercial payers, Medicare and other MACs to advance reimbursement of scalp cooling and improve accessibility and affordability for patients.



The market

The market

DigniCap minimizes chemotherapy-induced hair loss for cancer patients with solid tumors. Globally there are over 20 million incidences of cancer diagnosed annually, with 2 million diagnoses occurring in the U.S. each year, and by 2040 the global cancer burden is projected to reach 28 million new incidences solely due to growth and aging of the population. In the U.S. it is estimated that 39 out of 100 women and 40 out of 100 men will develop cancer during their lifetime.

Scalp cooling is primarily used today during the treatment of breast cancer, the most common type of cancer in

the world. Globally 2.3 million cases of breast cancer are diagnosed annually, with 311,000 of those in the United States. Scalp cooling is also used by patients with other solid tumors such as ovarian, uterine, endometrial, cervical, and prostate cancers. Non-breast solid tumors represent nearly one million patients in the U.S annually.

Dignitana estimates that up to 60 percent of all cancer patients are on regimens that are compatible with DigniCap. Additionally published studies have found that 8-10 percent of female patients refuse chemotherapy due to concern over hair loss, and 96 percent of potential patients surveyed were interested in scalp cooling.

Market development

The DigniCap Scalp Cooling System is clinically proven to reduce hair loss in cancer patients undergoing chemotherapy for solid tumors. The DigniCap Scalp Cooling System has been marketed worldwide since 2009 and received FDA clearance for the US market in 2015. DigniCap was the first scalp cooling system to receive FDA clearance, with only two other systems now on the market that received clearance more recently.

The DigniCap Delta model was introduced in 2019 and is a smaller, single-patient device providing optimal outcomes and improved ease of use for clinicians and patients. In 2019 DigniCap Delta received CE Marking for Europe and FDA clearance for the U.S., followed by TGA clearance for Australia.

To increase awareness and utilization of scalp cooling Dignitana works with patient advocacy organizations and interest groups in the cancer care community. Dignitana's ongoing sponsorship of Susan G. Komen, the largest breast cancer advocacy group in the world, is an example of this, in addition to numerous partnerships with foundations across the United States.

In most of the world scalp cooling is not a standard option for cancer care. The acceptance, market penetration and utilization of this treatment vary widely, providing significant opportunities for Dignitana all over the world.

Dignitana is committed to advancing the science of scalp cooling by supporting clinical trials and research initiatives among DigniCap users. The Company has initiated several studies that could expand usage to new user groups and show improvements with existing regimens that have exhibited inferior results with scalp cooling previously.



”

I am so grateful and blessed to have a full head of hair after all my treatment. It has allowed me to still look and feel like myself while going through the hardest time of my life.

– Sara



Financial information and comments

DIGNITANA GROUP

Revenues

Group revenues are generated by direct sales of systems, leasing of systems to health care providers, pay-per treatment fees, service and maintenance agreements sales of individual caps and kit accessories. For the

Fourth quarter 2023 net sales amounted to 21,266 TSEK (20,245), an increase over the same period 2022 by 1,021 TSEK representing 5 percent growth.

For 2023 in total net sales amounted to 86,063 TSEK (72,995), an increase over 2022 by 13,068 TSEK giving 18 percent growth.

Dignitana operates by two business models: in the U.S. market DigniCap Delta systems are leased to health care providers and the Company generates revenues from the leasing contracts through monthly leasing fees as well as payment for treatments and sales of products related to patient treatments. Outside the U.S, revenues are generated by sales of DigniCap Delta systems, frequently combined with service and maintenance agreements, as well as the sale of patient-related products and consumables.

The U.S. is still the driver in placing DigniCap Delta on the market using the leasing business model. In the first half of 2023 the Company focused on reallocating less utilized machines in some facilities to higher usage facilities with increasing demand. This enables the Company to reach more patients with less investment and cost, improve patient outcomes, and thereby achieve higher growth. At the end of 2023 Dignitana again is growing in number of DigniCap Deltas.

Reallocation of devices to optimize utilization will continue as part of normal business operations as the market develops.

Dignitana's revenue and costs comprise of different currencies such as USD, EUR, and SEK. Operational exchange rate balance effects are recognized in the income statement under other operating income and in other operating expenses. In Q4 2023 net exchange rate effects amounted to 242 TSEK (-125). For the full year net exchange rate effects was 580 TSEK (9,428). In Q4 2022 internal loans were redirected from USD to SEK and this has reduced the revaluation effect related to exchange fluctuations in 2023.

Operating Expenses and Operating Result

Operating expenses including Personnel expenses decreased during the quarter compared to the same period last year by 3,635 TSEK and amounted to -15,774 TSEK (-19,409). The company has been limiting the use of external consultants during the fourth quarter and the focus has mainly been on internal processes.

Depreciation and amortization in the Group amounted to -3,855 TSEK (-3,677) for the fourth quarter and -15,112 TSEK (-13,799) for the total year.

The operating result after depreciation for the Group for the fourth quarter was -3,717 TSEK (-10,927). For total 2023 the operating result was -15,026 TSEK (-20,614). Thereby EBITDA for the fourth Quarter is positive at 138 TSEK (-7,250) and even positive for the full year at 86 TSEK (-6,815).

Financial net

The financial net was -1226 TSEK (-1069) in Q4 and -2,202 TSEK (-1,782) for whole 2023, mainly affected by debt-related interest.

Employees

At the close of the period the Company had 27 (29) employees.

Cash Flow and Financial Position

Consolidated cash flow from operating activities during the quarter was -465 TSEK (-7,557). Total cash flow for the period was -517 TSEK (2260). For the full year the operating activities generated -5,744 TSEK (-18,164) in cash flow. Total cash flow for the year was -2,501 TSEK (-6,264).

Cash and cash equivalents at the end of the quarter amounted to 6,027 TSEK (8,869). This includes asset financing from Union Business Leasing, Inc. that has been concluded to facilitate capitalized equipment on the US market. The asset financing is related to an existing Master Loan and Security Agreement with UBL. The cash also includes 5 MSEK in loan from the largest owner Agarthia and 5 MSEK in a joint three-year loan from Handelsbanken and Almi Företagspartner that has been taken out in Q3.

Board and Management are continuously monitoring the financial position of the Company and are of the opinion that current business plans, in conjunction with various available options for credit facilities, are sufficient financial resources to cover working capital needs for the coming 12-month period.

CAPEX

Capex amounted to 1,075 TSEK (1,235) in the quarter in tangible assets and for total 2023 capital expenditures was 3,796 TSEK (3,130).

The share

Dignitana has been listed on First North Growth Market since November 2011 after having been listed on Spotlight Market in Stockholm since June 2009.

Dignitana AB

TICKER	DIGN
Market Cap December 30	154 MSEK
Number of shareholders, approximately	2,229
Share price December 30	2.18 SEK
Number of shares traded during the quarter	1,520,304
Number of shares outstanding December 30	70,474,155
Registered share capital	7,047,416 SEK
Par value	0.1 SEK
Certified Adviser	Redeye

Dignitana has only one category of shares, where each share carries one vote and equal rights to the Company's assets and profits. The Company has over time issued new shares and stock option programs and at the general meeting in May 2023 a decision was taken to issue a maximum of 1,800,000 employee warrants to key employees of the Company. The period for the employee stock warrants runs from June 2023 to June 2026.

Largest Shareholders

29 DECEMBER 2023	HOLDINGS	PERCENT
AGARTHA AB	20,500,000	29.09%
SWEDBANK ROBUR MICROCAP	5,415,000	7.68%
AVANZA PENSION	4,915,492	6.97%
HANDELSBANKEN MICROCAP SVERIGE	4,681,880	6.64%
UBS FINANCIAL SERVICES INC	4,189,739	5.95%
FÖRSÄKRINGSAKTIEBOLAGET SKANDIA PUB	2,601,714	3.69%
FE SMÅBOLAG SVERIGE	1,799,900	2.55%
TECHNOVOBIS AB	1,790,593	2.54%
POURSAMAD, AMIR	1,515,449	2.15%
RÜLF, SEMMY	1,015,058	1.44%
TOTAL	48,424,825	68.71%
OTHER SHAREHOLDERS	22,049,330	31.29%
TOTAL	70,474,155	100.00%

Source: Euroclear



” I wanted to feel as normal as possible and I wanted control over one thing in my life - and with DigniCap I could control my hair!”

- Karah



Risk factors

An investment in securities is associated with risk. Dignitana's activities are affected, and may be affected, by several factors which cannot be completely controlled by the Company. There are risks both in terms of circumstances attributable to Dignitana and those which have no specific connection with the Company.

The non-definitive list of the Company's risks pertains, but is not limited, to: patents, key personnel, growth management, management, restructuring, development costs, competitors, dependence on individual customers, customers, authorization and registration, chemotherapy without side effects, alternative cancer treatment methods, distributors and manufacturers, profitability and future capital requirements, political risk, geopolitical risks, pandemic risks, regulatory or change of laws, disputes and currency risks.

Risks related to COVID-19

The outbreak of COVID-19 continues to have an impact on the healthcare system of some countries, and in the United States specifically this has resulted in significant staffing challenges for healthcare facilities. This may affect the Company's opportunities to reach customers but also customers' ability to offer scalp cooling as a form of treatment. This could potentially impact the Company financially, although it is not possible to make a full assessment.

Risks related to the Russian invasion of Ukraine

The company's assessment is that the ongoing military conflict in Ukraine should not have any immediate significant effect on the operations. Indirect effects such as increases in energy costs and transportation, increased lead time of components and general cost increases could have some impact on the operations but are deemed as manageable. If the conflict spreads to more territories, this assessment could change. USA is the group's primary market from a sales and supply perspective.

The Board is ultimately responsible for managing and monitoring these risks. Ongoing management is delegated to the CEO, who in turn reports to the Board.

For a detailed explanation of these risk factors view the 2022 Annual Report posted at <https://dignitana.com/investor-relations/financial-reports/>

Other information

Forward-looking statements

This report may contain statements, estimates or projections that constitute "forward-looking statements." Generally, the words "believe", "expect", "intend", "estimate", "anticipate", "project", "will" and similar expressions identify forward-looking statements, which generally are not historical in nature. Forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the Dignitana historical experience or future projects.

Accounting principles

The consolidated financial statements comprise of Dignitana AB and its subsidiaries Dignitana Inc. and Dignitana S.r.l.

This interim report is prepared in accordance with Swedish GAAP, BFN 2012:1 (K3). The accounting policies remain unchanged compared with the preceding year and are the same principles that were applied for the Annual Report 2022.

Financial statements are presented in SEK, the functional currency of Dignitana AB. Assets and liabilities are translated and presented at the closing rate and the Income statement is translated and presented at period average exchange rates.

For a detailed explanation of accounting principles view the 2022 Annual Report posted at

<https://dignitana.com/investor-relations/financial-reports/>
This Interim Report has not been reviewed by the Group's Auditor.

Board assurance

The Board of Directors and Chief Executive Officer declare that this Interim Report provides a fair view of the Company's operations, financial position and results, and describes material risks and uncertainties facing the Company.

Dignitana AB

Corporate Registration Number: 556730-5346

Lund, 15 February 2024

Dignitana AB (publ) Board of Directors

Klas Arildsson
Chairman of the Board

William Cronin
Deputy Chairman of the Board

Lina Karlsson
Board member

Richard Dilorio
Board member

Christian Lindgren
Board member

Ljubo Mrnjavac
Board member

Income Statement – Dignitana Group, TSEK

DIGNITANA GROUP	Q4 2023	Q4 2022	Full year 2023	Full year 2022
Operating Income				
Net sales	21,266	20,245	86,063	72,995
Capitalized work for own account	0	431	0	431
Other operating income	650	745	2,962	10,423
Total Operating Income	21,916	21,421	89,025	83,849
Operating expense				
Goods for Resale	-6,004	-9,262	-27,092	-27,049
Operating expense	-6,786	-8,023	-24,985	-28,579
Personnel expense	-8,694	-11,085	-35,988	-34,289
Depreciation and amortization of tangible and intangible assets	-3,855	-3,677	-15,112	-13,799
Other operating expenses	-294	-301	-874	-747
	-25,633	-32,348	-104,051	-104,463
Operating profit (loss)	-3,717	-10,927	-15,026	-20,614
Result from financial investments				
Other Interest income and similar items	232	15	1,109	616
Interest expenses and similar items	-1,458	-1,084	-3,311	-2,398
	-1,226	-1,069	-2,202	-1,782
Profit after financial items	-4,943	-11,996	-17,228	-22,396
Profit before tax	-4,943	-11,996	-17,228	-22,396
Tax on profit for the period	-135	-15	-135	-15
Results for the Period	-5,078	-12,011	-17,363	-22,411
Average number of shares before and after dilution	70,474,155	69,343,551	70,474,155	66,130,254
Earnings per share before and after dilution, SEK	-0.07	-0.17	-0.25	-0.34

Balance Sheet – Dignitana Group, TSEK

DIGNITANA GROUP	2023-12-31 2023	2022-12-31 2022
ASSETS		
FIXED ASSETS		
Intangible assets		
Capitalized expenses for development	2,584	7,139
	2,584	7,139
Tangible assets		
Equipment, tools and installations	140	164
Machinery and other technical facilities	37	54
Leasing machines	19,849	26,952
	20,026	27,170
Financial assets		
Other long term receivables	409	175
	409	175
Total Fixed Assets	23,019	34,484
CURRENT ASSETS		
Inventories and similar		
Finished goods and goods for resale	7,413	5,053
	7,413	5,053
Current Receivables		
Accounts Receivable	4,915	6,505
Current Tax Assets	0	0
Other Current Receivables	422	756
Prepaid expenses and accrued income	3,035	2,884
	8,372	10,145
Cash and Bank Balances	6,027	8,869
Total Current Assets	21,812	24,067
Total Assets	44,831	58,551
EQUITY AND LIABILITIES		
Equity		
Share Capital	7,047	7,047
Unregistered share capital	0	0
Ongoing new issue	0	0
Other contributed capital	246,550	245,866
Other equity including profit for the year	-246,333	-228,663
Total Equity	7,264	24,250
Provisions		
Other provisions	409	187
	409	187
Long Term Liabilities		
Other long term liabilities	6,077	8,614
Total Long Term Liabilities	6,077	8,614
Current Liabilities		
Liabilities to credit institutions	13,027	9,653
Accounts payable	6,065	5,575
Other current liabilities	6,598	1,909
Accrued expenses and deferred income	5,391	8,363
Total current liabilities	31,081	25,500
Total liabilities	37,158	34,114
Total Equity and Liabilities	44,831	58,551

Consolidated Statement of Changes in Equity – Dignitana Group, TSEK

DIGNITANA GROUP	Sharecapital	Other contributed capital	Retained earnings, incl. net loss for the year	Total equity
Opening equity on 1/1/2022	6,506	222,692	-198,012	31,186
Net loss for the period			-22,411	-22,411
Share warrants		378		378
Option program 2022			960	960
New share issue	542	24,313		24,855
Issue costs		-1,518		-1,518
Change in translation difference relating to subsidiaries			-9,201	-9,201
Closing equity on 12/31/2022	7,047	245,866	-228,663	24,250
Net loss for the period			-17,363	-17,363
Share warrants		684		684
Change in translation difference relating to subsidiaries			-307	-307
Closing equity on 12/31/2023	7,047	246,550	-246,333	7,264

Statement of Cash Flows – Dignitana Group, TSEK

DIGNITANA GROUP	Q4 2023	Q4 2022	Full year 2023	Full year 2022
Operating activities				
Profit after financial investments	-4,943	-11,996	-17,228	-22,396
Adjustments for items not affecting cash flows, etc	5,018	5,218	16,835	6,178
Tax paid	0	-17	-16	-59
Cash flow from operating activities before changes in working capital	75	-6,795	-409	-16,277
Cash flow from changes in working capital				
Change in inventories	-2,179	1,305	-3,549	813
Change in other current receivables	-129	-593	1,407	-1,684
Change in other current liabilities	1,768	-1,474	-3,193	-1,016
Cash flows from operating activities	-465	-7,557	-5,744	-18,164
Investing activities				
Investments in intangible assets	0	-431	0	-431
Investments in tangible assets	-1,458	-895	-4,597	-2,790
Proceeds from sale of tangible assets	441	91	1,034	91
Investments in other financial fixed assets	-58	0	-233	0
Cash flows from investing activities	-1,075	-1,235	-3,796	-3,130
Financing activities				
New share issue	0	24,855	0	24,855
Issue expenses	0	-1,437	0	-1,518
Options issued	0	0	684	378
New loans	0	0	5,000	10,000
Repaid loans	0	-10,000	0	-10,000
Changes in long and short term liabilities to credit institutions	1,023	-2,366	1,355	-8,685
Cash flow from financial activities	1,023	11,052	7,039	15,030
Cash flow for the period	-517	2,260	-2,501	-6,264
Cash and cash equivalents at beginning of period				
Cash and cash equivalents at beginning of period	6,961	6,737	8,869	14,501
Exchange-rate differences in cash and cash equivalents				
Exchange-rate differences in cash and cash equivalents	-417	-128	-341	632
Cash and cash equivalents at end of period	6,027	8,869	6,027	8,869

Income Statement – Dignitana AB, TSEK

DIGNITANA AB, PARENT COMPANY	Q4 2023	Q4 2022	Full year 2023	Full year 2022
Operating Income				
Net sales	3,347	3,789	14,290	12,140
Capitalized work for own account	0	431	0	431
Other operating income	628	60	2,870	9,453
Total Operating Income	3,975	4,280	17,160	22,024
Operating expense				
Goods for Resale	-315	-3,197	-2,516	-5,911
Operating expense	-4,320	-13,658	-10,462	-21,666
Personnel expense	-4,033	-4,182	-16,245	-10,242
Depreciation and amortization of tangible and intangible assets	-1,155	-1,144	-4,617	-6,659
Other operating expenses	-155	-159	-734	-431
	-9,978	-22,340	-34,574	-44,909
Operating profit (loss)	-6,003	-18,060	-17,414	-22,885
Result from financial investments				
Other Interest income and similar items	1,036	391	1,912	992
Interest expenses and similar items	-1,254	-696	-2,120	-712
	-218	-305	-208	280
Profit after financial items	-6,221	-18,365	-17,622	-22,605
Profit before tax	-6,221	-18,365	-17,622	-22,605
Tax on profit for the period	0	0	0	0
Results for the Period	-6,221	-18,365	-17,622	-22,605

Balance Sheet – Dignitana AB, TSEK

DIGNITANA AB, PARENT COMPANY	2023-12-31	2022-12-31
ASSETS		
FIXED ASSETS		
Intangible assets		
Capitalized expenses for development	2,564	7,116
	2,564	7,116
Tangible assets		
Equipment, tools and installations	44	0
Other machinery and other technical facilities	37	54
Leasing machines	22	59
	103	113
Financial assets		
Participations in group companies	66,198	66,198
Receivable from group companies	8,284	10,698
Other long term receivables	409	175
	74,891	77,071
Total Fixed Assets	77,558	84,300
CURRENT ASSETS		
Inventories and similar		
Finished goods and goods for resale	3,265	2,766
	3,265	2,766
Current Receivables		
Accounts Receivable	549	1,470
Receivables from group companies	1,376	0
Other Current Receivables	332	667
Prepaid expenses and accrued income	893	446
	3,150	2,583
Cash and Bank Balances	899	5,455
Total Current Assets	7,314	10,804
Total Assets	84,872	95,104

Balance Sheet – Dignitana AB, TSEK

DIGNITANA AB, PARENT COMPANY	2023-12-31	2022-12-31
EQUITY AND LIABILITIES		
Equity		
Restricted equity		
Share Capital	7,047	7,047
Unregistered share capital	0	0
Fund for development expenses	2,564	7,116
	9,611	14,163
Non-restricted equity		
Share premium reserves	246,550	245,866
Other non-restricted equity	-174,123	-156,070
Results for the period	-17,622	-22,605
	54,805	67,191
Total Equity	64,416	81,354
Provisions		
Other provisions	409	175
	409	175
Long Term Liabilities		
Other long term liabilities	2,848	0
Total Long Term Liabilities	2,848	0
Current Liabilities		
Liabilities to credit institutions	1,805	0
Accounts payable	849	921
Current payable to group company	4,588	6,592
Other current liabilities	6,110	1,345
Accrued expenses and deferred income	3,847	4,717
Total current liabilities	17,199	13,575
Total liabilities	20,047	13,575
Total Equity and Liabilities	84,872	95,104

Financial calendar

23 May 2024	2023 Annual Report
23 May 2024	Q1 Report
23 May 2024	Annual General Meeting
22 August 2024	Q2 Report
21 Nov 2024	Q3 Report
20 Feb 2025	2024 Year End Report

All financial reports are available at
www.dignitana.com/investor-relations/financial-reports/

Contact information

Dignitana AB

Traktorgränden 3, 226 60 Lund
+46 (0) 46-16 30 90
info@dignitana.com
investorrelations@dignitana.com
www.dignitana.com

Certified Adviser

Redeye AB
+46 8 121 576 90
certifiedadviser@redeye.se
www.redeye.se